- Home
- MEDP vs TOL Comparison
MEDP vs TOL Comparison
Compare MEDP & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEDP
- TOL
- Stock Information
- Founded
- MEDP 1992
- TOL 1967
- Country
- MEDP United States
- TOL United States
- Employees
- MEDP N/A
- TOL N/A
- Industry
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- TOL Homebuilding
- Sector
- MEDP Health Care
- TOL Consumer Discretionary
- Exchange
- MEDP Nasdaq
- TOL Nasdaq
- Market Cap
- MEDP 13.4B
- TOL 13.8B
- IPO Year
- MEDP 2016
- TOL N/A
- Fundamental
- Price
- MEDP $584.91
- TOL $134.95
- Analyst Decision
- MEDP Hold
- TOL Buy
- Analyst Count
- MEDP 11
- TOL 15
- Target Price
- MEDP $451.70
- TOL $150.87
- AVG Volume (30 Days)
- MEDP 354.5K
- TOL 1.3M
- Earning Date
- MEDP 10-22-2025
- TOL 12-08-2025
- Dividend Yield
- MEDP N/A
- TOL 0.74%
- EPS Growth
- MEDP 25.36
- TOL N/A
- EPS
- MEDP 14.32
- TOL 13.61
- Revenue
- MEDP $2,358,373,000.00
- TOL $10,876,787,000.00
- Revenue This Year
- MEDP $19.15
- TOL $0.38
- Revenue Next Year
- MEDP $8.91
- TOL N/A
- P/E Ratio
- MEDP $40.85
- TOL $9.92
- Revenue Growth
- MEDP 13.88
- TOL 3.26
- 52 Week Low
- MEDP $250.05
- TOL $86.67
- 52 Week High
- MEDP $625.00
- TOL $169.52
- Technical
- Relative Strength Index (RSI)
- MEDP 66.03
- TOL 48.38
- Support Level
- MEDP $571.03
- TOL $132.51
- Resistance Level
- MEDP $595.00
- TOL $140.33
- Average True Range (ATR)
- MEDP 19.57
- TOL 4.14
- MACD
- MEDP 2.23
- TOL -0.08
- Stochastic Oscillator
- MEDP 65.10
- TOL 58.40
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. It has its headquarters in Horsham, Pennsylvania.